Published in final edited form as:

Int J Gynecol Cancer. 2018 September ; 28(7): 1432–1437. doi:10.1097/IGC.0000000000001310.

Use of a Sentinel Lymph Node Biopsy Algorithm in a South African Population of Patients with Cervical Cancer and High Prevalence of HIV Infection.

Leon C Snyman, FCOG (SA)¹, Emma P Bryant, FCOG (SA)¹, Elize I Wethmar, FCOG (SA)¹, Tom de Greve, MD¹, Florette Reyneke, MBChB², Mike M Sathekge, PhD², Barend G Lindeque, MD¹, and Nadeem R. Abu-Rustum, PhD^{3,4}

¹Gynaecologic Oncology Unit, Department Obstetrics & Gynaecology, University of Pretoria, Pretoria, South Africa.

²Department Nuclear Medicine, University of Pretoria, Pretoria, South Africa.

³Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Centre, New York, NY, USA

⁴Department of Obstetrics and Gynaecology, Weill Cornell Medical College, New York, NY, USA

Abstract

Objectives: Cervical cancer is common in resource poor settings with high prevalence of tuberculosis, pelvic inflammatory disease (PID) and HIV infection. There is no data regarding the SLN algorithm in these high-risk cancer populations. Our objectives were to establish the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the SLN algorithm in cervical cancer, and to compare the detection rate of ICG versus blue dye versus ^{99m}Tc-Nanocolloid.

Methods: This prospective study was conducted at the University of Pretoria. ^{99m}Technetium nanocolloid tracer (^{99m}Tc), indocyanine green (ICG) dye, and methylene blue (MB) was used to detect SLNs. Pathological ultrastaging was performed on H&E negative nodes.

Results: Results of 72 women were analysed. The mean age was 47.2 years, 5.5% had a history of TB, 18.1% had PID, and 65.3% were HIV positive. The SLN detection rate was 65.3%. Detection rate of MB was 56.9%, ^{99m}Tc 69.4%, ICG 87.5% and the combination of MB and ^{99m}Tc 91.7%. Pelvic nodal metastases occurred in 26.4%. The sensitivity, specificity, NPV, and PPV of SLNB was 85.7%, 100%, 100%, and 98.33%, respectively. The false-negative rate was 14.3%, and 0% if the algorithm was applied.

Conclusions: The SLN algorithm is a feasible option for use in cervical cancer women with a high prevalence of HIV infection. The detection rate is generally lower, but in select sub-groups of women, it was comparable to that reported elsewhere. This is the first report of the use of SLNB in a substantial group of HIV-infected women.

INTRODUCTION

Cervical cancer is the second most common cancer in South African women, with an estimated incidence of 31.5 per 100,000 women¹. Although the International Federation of Gynecology and Obstetrics (FIGO) classification system of cervical cancer does not include pelvic lymph node status, it is well recognized and accepted that lymph node metastasis is an important risk factor for recurrence and death in patients with cervical cancer.^{2,3} Oncologic information of the lymph nodes is important for the planning of optimal treatment and adjuvant treatment strategies in patients with early-stage disease. For the purpose of this study, early-stage cervical cancer was defined as disease diagnosed and clinically staged as FIGO stage I to IIA.

Surgical treatment of early-stage cervical cancer consists of radical hysterectomy and pelvic lymphadenectomy with or without para-aortic lymphadenectomy. In approximately 80% of women, lymphadenectomy will be unnecessary. A sentinel lymph node biopsy (SLNB) algorithm has been proposed as a reasonable alternative to full lymphadenectomy in these patients.

The reported pooled detection rate of SLNs in cervical cancer is 89%, and the reported pooled sensitivity rate is 90%.⁴ SLNB procedures appear to be more accurate with smaller tumors and in patients with bilaterally detected SLNs.^{5–8}

Cormier et al. proposed an SLN algorithm to overcome the high false-negative rate (FNR) of SLNBs. This algorithm includes a side-specific evaluation and recommends lymphadenectomy on the side(s) where no SLNs are detected, as well as the removal of clinically enlarged lymph nodes. This strategy resulted in a sensitivity of 100% and negative predictive value (NPV) of 100%.⁹ A review of 46 studies with 4,130 patients concluded that in patients with tumors smaller than 40 mm and no preoperative or intraoperative suspicious nodes with bilateral negative SLNs after ultrastaging, the FNR was 0.08%.¹⁰

Prospective data with regard to SLN procedures in women with cervical cancer are sparse. Niikura et al. reported on the outcomes of 35 women with FIGO stage IA1 to IIA1 disease, of whom pelvic lymphadenectomy was omitted in 23 women who had negative bilateral SLNs.¹¹ There were no recurrences among the women who underwent SLNB; furthermore, the incidence of lymphedema was 8.7% in those who underwent SLNB compared with 42% in those who underwent systematic pelvic lymphadenectomy.

There are no reported data on the ability of SLNB to predict pelvic lymph node status in a population of women with early-stage cervical cancer and high prevalence of human immunodeficiency virus (HIV) infection. South Africa has the highest HIV infection rate in the world, as well as high rates of related conditions such as pelvic inflammatory disease (PID), tuberculosis (TB), and human papilloma virus (HPV) infection. In 2012, an estimated 12.2% of the South African population was infected with HIV (14.4% of women and 9.9% of men).¹² In 2015, more than one million South Africans were newly enrolled for HIV care, of whom 11.7%, or nearly 128,000 people, were designated as TB cases.¹³ The prevalence of high-risk HPV among the general female South African population is as high as 54.3%.¹⁴ How these infections affect the lymphatic channels and the lymph nodes in this population is

unknown; however, it is evident that South African women face unique healthcare challenges, and data from well-developed countries need to be verified before they can be applied in the clinical practices of this region.

This study aimed to investigate the sensitivity, specificity, and positive and negative predictive values (PPVs and NPVs, respectively) of SLNB in South African women. The study also compares the use of SLNB in HIV-positive versus HIV-negative patients and investigates factors influencing detection rates.

MATERIALS AND METHODS

As part of this prospective study, which was conducted at the academic hospitals of the Gynaecological Oncology Unit of the Department of Obstetrics and Gynaecology, University of Pretoria, women diagnosed with early-stage cervical cancer (FIGO stage IA to IIA) and scheduled for primary surgical treatment were recruited for enrolment. Their surgical treatment consisted of laparoscopic or open radical hysterectomy and pelvic lymphadenectomy.

SLN detection was achieved using ^{99m}Tc Technesium nanocolloid tracer (^{99m}Tc), indocyanine green (ICG) dye, and/or methylene blue dye. ^{99m}Tc was injected into the cervix of some of the women scheduled for surgery one day before the procedure, and methylene blue (2 ml at the 3 o' clock and 9 o' clock positions, respectively) was injected preoperatively after the induction of general anaesthesia. In some women, ICG was also used. After the identification and removal of all SLNs, total pelvic lymph node dissection was performed in addition to the appropriate type of hysterectomy with or without bilateral salpingo-oophorectomy. Para-aortic lymphadenectomy was performed at the discretion of the treating gynecologic oncologist.

The SLN and the remainder of the pelvic lymph nodes were sent separately for histological examination. Each SLN was bisected into two halves. One half was managed as a frozen section, while the other half was processed and stained using hematoxylin and eosin (H&E), as per normal routine. If the SLN was found to be negative for metastases, the node then underwent ultra-staging with further sectioning and immunohistochemical staining.

Calculations

The detection rate was calculated as the number of patients with at least one detected pelvic SLN divided by the total number of patients who underwent SLN mapping. Diagnostic performance was calculated for hemi-pelvises with at least one SLN harvested. Exact 95% confidence intervals (CIs) for the proportions were calculated, and subgroup analyses were performed using a two-sided χ^2 test or Fisher's exact test ($\alpha=0.05$).

Ethical considerations

The Research Ethics Committee of the Faculty of Health Sciences, University of Pretoria, granted ethics approval for the study (434/2014).

RESULTS

Of 78 women enrolled on the study, 72 were evaluable for analysis. Six patients were excluded due to death after recruitment but before surgery (n=1), missing hospital files (n=1), or upstaged disease (n=4). Of the patients who were upstaged, one was diagnosed with lung metastases on fluorodeoxyglucose–positron emission tomography/computed tomography (FDG–PET/CT) scanning, two were upstaged to stage IIB and one to stage IIB disease during examination under anaesthesia immediately prior to undergoing surgery. The mean age of the patients was 47.2 years (range, 32–77 years). Other patient demographic data are listed in Table 1. Thirteen women (18.1%) had undergone previous surgery. Four patients (5.5%) had a history of TB, of whom 3 (4.2%) had pulmonary TB and 1 (1.4%) had abdominal TB. Thirteen patients (18.1%) were previously diagnosed with PID. Four women (5.6%) had FIGO stage IA2, 48 women (66.7%) had FIGO stage IB1, 13 women (15.3%) had FIGO stage IB2, four women (5.6%) had FIGO stage IIa1 and five women (6.9%) had FIGO stage IIa2 cervical cancer.

HIV Status

Forty-seven women (65.3%) were HIV positive. Forty-three (91.5%) of these women were undergoing anti-retroviral (ARV) therapy, 28 of them (80.8%) for more than 6 months. The mean CD4 count in the HIV-positive women was 434.60 cells/ μ L (range, 43–950; SD, 222.13; SEM, 33.11; 95% CI, 367.86–501.34), and the mean viral load was 24916.29 copies/ μ L (range, undetectable – 666811; SD, 119540.02; SEM, 21470.02; 95% CI, 18931.35–68763.93). HIV-infected women were significantly younger and had lower body mass indexes (BMIs). Furthermore, significantly fewer women in this group had tumors $\geq$ 2 cm in size compared to those who were HIV negative. There were no statistically significant differences in stage distribution between the two HIV groups.

SLN detection

SLNs were detected in 47 patients, yielding a detection rate of 65.3%. Bilateral SLN detection was achieved in 22 patients, yielding a bilateral detection rate of 30.5%. The histologically confirmed SLN count was 135 nodes, of which 62 were detected on the left side and 73 on the right side (mean count, 3.0 nodes; range, 1–9; SD, 1.92; SEM, 0.29; 95% CI, 2.42–3.77).

In 66 hemi-pelvises, there were 6 true positives, 59 true negatives, and 1 false-negative SLN. Per definition, false-positive SLNs do not exist.

The sensitivity, specificity, NPV, and PPV of SLNB in this patient population was 85.7%, 100%, 100%, and 98.33%, respectively. The false-negative rate was 14.3%.

For the HIV negative group, the sensitivity, specificity, NPV and PPV of ALNB was 100%, 100%, 100% and 100% respectively, and the false-negative rate was 0%. For the HIV positive group, the respective values were 83.3%, 100%, 100% and 97.62%, with a false-negative rate of 8.3%.

Methods of SLN detection

Methylene blue was administered to all 72 patients. Thirty-six patients (50%) also received intracervically administered ^{99m}Tc with lymphoscintigram examinations. Eight patients (11.1%) received ICG as well. Thirty-six patients (50%) received methylene blue and ^{99m}Tc ; 3 (4.2%) received methylene blue and ICG, and 5 (6.9%) received methylene blue, ^{99m}Tc , and ICG.

SLNs were detected with methylene blue alone in 41 patients (56.9%). In the 36 women who received methylene blue and ^{99m}Tc , SLNs were detected by ^{99m}Tc in 25 patients (69.4%). SLNs were detected with ICG in 7 (87.5%) of the 8 patients who received ICG. The combination of methylene blue and ^{99m}Tc detected SLNs in 33 women (91.7%). The comparative detection rate data are listed in Table 2.

Nodal status

Seventy-one patients (98.6%) underwent full systematic pelvic lymphadenectomy. One patient (1.4%) had morbidly adherent lymph node metastases that were deemed unsafe to remove, and these nodes were only biopsied. This patient did not undergo a hysterectomy.

Nineteen patients (26.4%) had pelvic lymph node metastases. Patients with nodal metastases had significantly larger tumors (mean diameter 40.88 vs 23.26 mm; $p = 0.0087$) and were more likely to have tumors ≥ 2 cm (83.3% vs 40.7%; $p = 0.0019$) and grossly enlarged lymph nodes (66.7% vs 20.4%; $p = 0.0003$). The SLN detection rate in women without metastases was 72.2% compared to 44.4% in women with metastases ($p = 0.0332$).

BMI

The mean BMI of all patients was 27.51 kg/m². Twenty-seven women (37.5%) had a BMI < 25 kg/m², 45 (62.5%) had a BMI ≥ 25 kg/m², and 23 (31.9%) had a BMI ≥ 30 kg/m². The SLN detection rate was 77.7% in women with a normal BMI compared to 43.5% in those with a BMI ≥ 30 kg/m² ($p = 0.0140$).

FIGO stage

The SLN detection rate was significantly better in women with FIGO stage IA2 – IB1 disease compared to women with locally advanced disease. The comparative data for the two groups are listed in Table 2.

History of TB, PID, and the presence of pelvic adhesions

Twenty-seven women (37.5%) had a history of TB and/or PID and/or the presence of adhesions at the time of surgery, compared to 45 women (62.5%) who did not. The SLN detection rate in the TB/PID/adhesion group was 63% compared to 66.7% in the comparative group ($p = 0.7512$).

Bilharzia and TB

One patient had bilharzia ova reported in her lymph nodes, and another patient had TB reported in her lymph nodes. The patient with TB in her nodes was found to have micrometastases in her SLN; her non-SLNs were negative for metastases.

The SLNB algorithm

According to the algorithm, patients without mapping should undergo a full pelvic lymphadenectomy, and all enlarged or suspicious nodes should also be removed regardless of mapping. In this cohort, SLNB was associated with an FNR of 14.3%, as there was a false-negative SLNB in one patient. This patient had enlarged nodes on the side of lymph node metastases; if the algorithm were applied to this patient, there would have been no false-negatives, yielding an FNR of 0%.

DISCUSSION

Although the rate of HIV infection in South Africa is relatively high, the rate among this group of women was even higher, which was unexpected considering the study and recruitment designs were not structured to accrue more HIV-infected than non-infected women. Previous data from our Gynaecological Oncology Unit have demonstrated an HIV infection rate of 26% among women with cervical cancer, and this rate has been consistent among all stages through several years.¹⁵ Although there were no significant differences with regard to mean tumor diameter between the two groups, significantly more women in the HIV-negative group had tumors measuring ≥ 2 cm, despite similar stage distributions. This might be attributable to more screening in HIV-infected women on ARV treatment. HIV-infected women tended to have more previous episodes of TB infection, although due to the small number of patients, this difference did not reach statistical significance.

The almost similar proportion of HIV-positive and HIV-negative women with enlarged lymph nodes, as well as with nodal metastases, are somewhat unexpected, as one would have suspected higher rates of both in the HIV-infected group. The finding that there was no difference in the SLN detection rates between the two groups is an important finding, as there are no published data on the detection rate of SLNs in HIV-infected women.

Women with a BMI ≥ 30 kg/m² achieved a detection rate that was significantly lower than that of women with a BMI <25 kg/m² (43.5% vs 37.5%; $p = 0.0140$). BMI is therefore a significant factor in the detection of SLNs. This finding is consistent with similar findings in the published literature.¹⁶

Enlarged lymph nodes

Almost 32% of women had clinically enlarged lymph nodes. HIV status did not show an effect on macroscopic nodal status, with almost identical rates among the two groups. This is an unexpected finding, as one would expect a higher proportion of women to present with clinically enlarged nodes in the HIV-infected group.

The macroscopic appearance of lymph nodes in women with cervical cancer is not a good predictor of the presence of pelvic nodal metastatic disease in these women, with 52% of women with macroscopic enlarged nodes having metastatic disease in these enlarged nodes. The sensitivity, specificity, PPV, and NPV of enlarged nodes were 83.3%, 32.1%, 44.1%, and 75%, respectively. Macroscopic assessment based on lymph node size alone is not accurate for clinical decision making in the treatment of women with cervical cancer.

The overall SLN detection rate of 65% in this study population is lower than the detection rates published in the international literature. The detection rate of the combination of methylene blue and ^{99m}Tc were statistically significantly better than those of methylene blue alone or ^{99m}Tc alone. There was no statistically significant difference between methylene blue plus ^{99m}Tc compared to ICG alone. ICG performed better than methylene blue alone, although the difference did not reach statistical significance. The sample size of ICG was very small. These detection patterns are consistent with the published literature.^{17–24}

The SLN detection rate in women with no metastases was significantly higher than that of women with metastases (72.2% vs 44.4%, respectively). This too is consistent with the published literature.¹⁷

The better detection rate in node-negative women with early-stage cervical cancer is reassuring, as this might result in fewer unnecessary pelvic lymphadenectomy procedures in select patients if the SLNB algorithm is followed correctly.

Tumor size, as expected, was significantly associated with less nodal metastases. SLN detection was statistically significantly better in those with tumors <2 cm in largest diameter compared to those with tumors ≥ 2 cm (77.1% vs 54%, respectively; $p = 0.0411$). The published literature also shows a correlation between tumor size and detection rate, with significantly better detection rates when the tumor size is less than 2 cm.⁶ When 4 cm is used as a size cut-off, there is also a significant difference in detection rates.²⁵ The smaller the tumor, the better the detection rate of SLNs.²⁶

The SLN detection rate was significantly higher in the group of patients with stage IA – IB1 disease compared to those with stage IB2 – IIA2 disease (74.5% vs 42.9%, respectively; $p = 0.0110$). This correlates with the findings of better detection in smaller tumors, as well as in women with no nodal metastases.

CONCLUSION

The SLN algorithm is a feasible option for use in South African women with early-stage cervical cancer and a high prevalence of HIV infection. The algorithm provides useful information on lymph node status that may carry adjuvant treatment implications. Although the detection rate is generally lower than that reported in the literature, in select sub-groups of women, the detection rate was comparable to that reported elsewhere.

The factors influencing SLN detection rates are pelvic lymph node status, tumor size, FIGO stage, and BMI. Women with smaller tumors, normal BMI, and lower stage of disease had statistically significantly better detection rates.

The procedure also has high sensitivity and the FNR for this cohort of women when using the Memorial Sloan Kettering SLN algorithm was 0%.

There is still a lack of prospective data on the use of SLN procedures in women with early-stage cervical cancer, and it is unclear what the effect on disease-free and overall survival will be should this technique be implemented in routine care. At this stage, it would be

reasonable to suggest the use of the SLN algorithm as part of the individualized care of select women.

The results reported here are the first with regard to SLNB in South African women with a high prevalence of HIV, TB, and PID. This is also the first report of the use of SLNB in a substantial group of HIV-infected women.

Acknowledgments

Source of Funding: Dr. NR Abu-Rustum is supported in part by the NIH/NCI Memorial Sloan Kettering Cancer Center Support Grant P30 CA008748.

REFERENCES

1. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer 2013.
2. Sevin BU, Lu Y, Bloch DA, et al. Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis. *Cancer* 1996;78:1438–1446. [PubMed: 8839549]
3. Delgado G, Bundy BN, Fowler WC Jr., et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. *Gynecol Oncol* 1989;35:314–320. [PubMed: 2599466]
4. Kadkhodayan S, Hasanzadeh M, Treglia G, et al. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. *Eur J Surg Oncol* 2015;41:1–20. [PubMed: 25454828]
5. Fader AN, Edwards RP, Cost M, et al. Sentinel lymph node biopsy in early-stage cervical cancer: utility of intraoperative versus postoperative assessment. *Gynecol Oncol* 2008;111:13–17. [PubMed: 18684499]
6. Yamashita T, Katayama H, Kato Y, et al. Management of pelvic lymph nodes by sentinel node navigation surgery in the treatment of invasive cervical cancer. *Int J Gynecol Cancer* 2009;19:1113–1118. [PubMed: 19820378]
7. Darlin L, Persson J, Bossmar T, et al. The sentinel node concept in early cervical cancer performs well in tumors smaller than 2 cm. *Gynecol Oncol* 2010;117:266–269. [PubMed: 20167355]
8. Ogawa S, Kobayashi H, Amada S, et al. Sentinel node detection with (99m)Tc phytate alone is satisfactory for cervical cancer patients undergoing radical hysterectomy and pelvic lymphadenectomy. *Int J Clin Oncol* 2010;15:52–58. [PubMed: 20087618]
9. Cormier B, Diaz JP, Shih K, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. *Gynecol Oncol* 2011;122:275–280. [PubMed: 21570713]
10. Tax C, Rovers MM, de Graaf C, et al. The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic review. *Gynecol Oncol* 2015;139:559–567. [PubMed: 26416173]
11. Niikura H, Okamoto S, Otsuki T, et al. Prospective study of sentinel lymph node biopsy without further pelvic lymphadenectomy in patients with sentinel lymph node-negative cervical cancer. *Int J Gynecol Cancer* 2012;22:1244–1250. [PubMed: 22864335]
12. Shisana O, Rehle T, Simbayi L, et al. South African national HIV prevalence, incidence and behaviour survey, 2012 Cape Town 2014 HSRC Press Available at: <http://www.hsrc.ac.za/uploads/pageContent/4565/SABSSM%20IV%20LEO%20final.pdf> Accessed on Jan 11 2018.
13. Organization WH. Global tuberculosis report 2016. 2016. World Health Organization. Global tuberculosis report 2016 Switzerland: WHO; 2016 Available at: <http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1> Accessed on Jan 11 2018.
14. Richter K, Becker P, Horton A, Dreyer G. Age-specific prevalence of cervical human papillomavirus infection and cytological abnormalities in women in Gauteng Province, South Africa. *S Afr Med J* 2013;103:313–317. [PubMed: 23971121]

15. Snyman LC, Zondagh BA, Dreyer G, et al. Urine cytology as a screening test for bladder infiltration in cervical cancer. *Int J Gynecol Cancer* 2006;16:1587–1590. [PubMed: 16884370]
16. Salvo G, Ramirez PT, Levenback CF, et al. Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. *Gynecol Oncol* 2017;145:96–101. [PubMed: 28188015]
17. Plante M, Renaud MC, Tetu B, et al. Laparoscopic sentinel node mapping in early-stage cervical cancer. *Gynecol Oncol* 2003;91:494–503. [PubMed: 14675667]
18. Buda A, Crivellaro C, Elisei F, et al. Impact of indocyanine green for sentinel lymph node mapping in early stage endometrial and cervical cancer: comparison with conventional radiotracer (99m)Tc and/or blue dye. *Ann Surg Oncol* 2016;23:2183–2191. [PubMed: 26714944]
19. Beavis AL, Salazar-Marioni S, Sinno AK, et al. Sentinel lymph node detection rates using indocyanine green in women with early-stage cervical cancer. *Gynecol Oncol* 2016;143:302–306. [PubMed: 27526991]
20. Buda A, Papadia A, Zapardiel I, et al. From conventional radiotracer Tc-99(m) with blue dye to indocyanine green fluorescence: a comparison of methods towards optimization of sentinel lymph node mapping in early stage cervical cancer for a laparoscopic approach. *Ann Surg Oncol* 2016;23:2959–2965. [PubMed: 27126631]
21. Plante M, Touhami O, Trinh XB, et al. Sentinel node mapping with indocyanine green and endoscopic near-infrared fluorescence imaging in endometrial cancer. A pilot study and review of the literature. *Gynecol Oncol* 2015;137:443–447. [PubMed: 25771495]
22. Rocha A, Dominguez AM, Lecuru F, Bourdel N. Indocyanine green and infrared fluorescence in detection of sentinel lymph nodes in endometrial and cervical cancer staging - a systematic review. *Eur J Obstet Gynecol Reprod Biol* 2016;206:213–219. [PubMed: 27750179]
23. Ruscito I, Gasparri ML, Braicu EI, et al. Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes – a meta-analysis. *Ann Surg Oncol* 2016;23:3749–3756. [PubMed: 27160526]
24. Van de Lande J, Torrensa B, Raijmakers PG, et al. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. *Gynecol Oncol* 2007;106:604–613. [PubMed: 17628644]
25. Yuan SH, Xiong Y, Wei M, et al. Sentinel lymph node detection using methylene blue in patients with early stage cervical cancer. *Gynecol Oncol* 2007;106:147–152. [PubMed: 17499345]
26. Zarganis P, Kondi-Pafiti A, Arapantoni-Dadioti P, et al. The sentinel node in cervical cancer patients: role of tumor size and invasion of lymphatic vascular space. In *Vivo* (Athens, Greece) 2009;23:469–473.

Table 1:

Demographic and histological data (N=72)

Demographic data			
	Mean	SD	Range
Age, years	47.21	9.09	32 – 77
Parity	3.10	1.63	0 – 8
Gravidity	3.28	1.69	0 – 8
BMI, kg/m ²	27.51	5.41	18.37 – 43.03
Histological data			
Tumour type		Number of patients (%)	
Squamous cell carcinoma		62 (86.1)	
Adenocarcinoma		6 (8.3)	
Adeno-squamous carcinoma		2 (2.8)	
Clear cell carcinoma		1 (1.4)	
Carcinosarcoma		1 (1.4)	

BMI, body mass index

Table 2:Comparative detection rates between MB, ^{99m}Tc and ICG

MB only		^{99}Tc only		MB + ^{99m}Tc		ICG only		P value
Detect rate%	n	Detect rate%	n	Detect rate%	n	Detect rate%	n	
56.9	72	69.4	36					0.2113
39.4	33			91.7	36			<0.0001
		69.4	36	91.7	36			0.0176
56.9	72					87.5	8	0.0959
		69.4	36			87.5	8	0.3042
				91.7	36	87.5	8	0.7114

Table 3:

Comparative data of early-stage disease versus locally advanced disease

	Stage IA – IB1 n = 51		Stage IB2 – IIA2 n = 21		P
	Mean	SD	Mean	SD	
Age, years	48.82	9.51	43.29	6.69	0.0179
Parity	3.14	1.71	3.00	1.45	0.7435
Gravidity	3.32	1.74	3.19	1.60	0.7697
BMI, kg/m ²	27.42	5.29	27.73	5.82	0.8269
Tumour diameter, mm	14.85	12.61	53.75	20.08	<0.0001
Macro SLN count	2.11	1.31	2.00	0.71	0.8097
Histology SLN count	3.11	2.05	2.56	1.24	0.4475
Pelvic node count	24.37	9.01	27.10	11.90	0.3032
	n	%	n		
HIV positive	36	70.6	11	52.4	0.1431
Previous tuberculosis	4	7.8	0	0	0.1910
Previous PID	11	52.4	2	9.5	0.0008
Previous surgery	8	15.7	5	23.8	0.4200
Adhesions	12	23.5	4	19.1	0.6852
Enlarged nodes	10	19.6	10	47.6	0.0166
Tumour ≥ 2 cm	16	31.4	21	100	<0.0001
Nodal metastases	8	15.7	10	47.6	0.0048
SLN detection rate	36	74.5	9	42.9	0.0110
Bilateral SLN detection	16	31.4	6	28.6	0.8160
Intra-op complications	6	11.8	1	4.8	0.3663
Post-op complications	8	15.7	5	23.8	0.4200

BMI, body mass index; SLN, sentinel lymph node; PID, pelvic inflammatory disease